Ronit Marcus
YOU?
Author Swipe
View article: Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis Open
Locally manufactured chimeric antigen receptor T-cell (CAR T) therapy enables rapid manufacturing and a substantially shorter vein-to-vein time. However, its clinical efficacy compared to commercial CAR T products remains unclear. This ret…
View article: CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia
CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia Open
Richter transformation (RT) is a serious complication of chronic lymphocytic leukaemia (CLL), with poor outcomes. While CAR T‐cells have shown promise in large B‐cell lymphoma, their efficacy in RT remains unclear, and the role of allogene…
View article: Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma Open
Although 3 commercial CD19-targeted chimeric antigen receptor (CAR) T-cell therapies are available for large B-cell lymphomas (LBCLs), no randomized clinical trials have compared their efficacy and safety. In this retrospective multicenter…
View article: Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells
Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells Open
Pulmonary function tests (PFTs) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive signif…
View article: Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study Open
Background: Previous studies by us and others have shown that broad-spectrum antibiotic exposure, particularly with PIM (piperacillin-tazobactam, imipenem, and meropenem), before CD19-chimeric antigen receptor T-cell (CAR-T) therapy is ass…
View article: CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia Open
Introduction: Richter transformation (RT) is a devastating complication of chronic lymphocytic leukemia (CLL), associated with poor outcomes. While the progressively expanding use of CAR-T cells in the setting of large B-cell lymphoma (LBC…
View article: CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes Open
Background: CAR T-cell therapy (CAR-T) results in a unique spectrum of toxicities, affecting morbidity, mortality, and quality of life. Traditionally, immunotoxicities like cytokine release syndrome (CRS) and immune effector cell-associate…
View article: Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <i>de novo</i> large B-cell lymphoma and transformed low-grade B-cell lymphoma
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <i>de novo</i> large B-cell lymphoma and transformed low-grade B-cell lymphoma Open
The activity of anti-CD19 CAR T cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety…
View article: The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy
The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy Open
INTRODUCTION: CAR-T therapy is an effective treatment for hematological malignancies. However, in recent years there is a growing body of literature suggesting adverse cardiovascular (CV) events among patients treated with CAR-T therapy. W…
View article: High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia
High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia Open
Background Tisagenlecleucel and brexucabtagene autoleucel have demonstrated remarkable efficacy and safety results in adult patients with relapsed/ refractory acute B lymphoblastic leukemia (R/R B-ALL). Long term follow-up of the ZUMA-3 tr…
View article: Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma
Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma Open
Patients with relapsed/refractory follicular lymphoma (R/R-FL) often require multiple treatment lines. We performed a phase 1b/2 single-center clinical trial of autologous point-of-care anti-CD19 chimeric antigen receptor (CAR) T-cells in …
View article: P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE Open
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Primary mediastinal B- cell lymphoma (PMBCL), a pathobiologically unique subtype of aggressive B cell lymphoma, has excellent prognosis in front-line se…
View article: P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Anti-BCMA chimeric antigen receptor (CAR) T-cell therapy showed excellent efficacy and safety in patients with relapsed/refractory multiple myeloma (R/R MM). Point…